Cannabics Pharmaceuticals Financials
CNBX Stock | USD 0.01 0.0004 4.00% |
With this module, you can analyze Cannabics financials for your investing period. You should be able to track the changes in Cannabics Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Cannabics |
Understanding current and past Cannabics Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cannabics Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Cannabics Pharmaceuticals' assets may result in an increase in income on the income statement.
The data published in Cannabics Pharmaceuticals' official financial statements usually reflect Cannabics Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cannabics Pharmaceuticals. For example, before you start analyzing numbers published by Cannabics accountants, it's critical to develop an understanding of what Cannabics Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Cannabics Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cannabics Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cannabics Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cannabics Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Cannabics Pharmaceuticals' management manipulating its earnings.
Cannabics Pharmaceuticals Stock Summary
Cannabics Pharmaceuticals competes with Biomx, Ascletis Pharma, Clearmind Medicine, Coeptis Therapeutics, and Quoin Pharmaceuticals. CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cnbx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.Instrument | USA OTC Stock View All |
Exchange | OTCQB Exchange |
ISIN | US13764M1009 |
Business Address | 3 Bethesda Metro |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | NYSE Composite |
Website | www.cnbxpharma.com |
Phone | 877 424 2429 |
Currency | USD - US Dollar |
You should never invest in Cannabics Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cannabics OTC Stock, because this is throwing your money away. Analyzing the key information contained in Cannabics Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cannabics Pharmaceuticals Key Financial Ratios
Generally speaking, Cannabics Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Cannabics Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Cannabics Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cannabics Pharmaceuticals reports annually and quarterly.Return On Equity | -42.89 | |||
Return On Asset | -1.0 | |||
Beta | 1.52 |
Cannabics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cannabics Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cannabics Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cannabics Pharmaceuticals competition to find correlations between indicators driving Cannabics Pharmaceuticals's intrinsic value. More Info.Cannabics Pharmaceuticals is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cannabics Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cannabics Pharmaceuticals' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cannabics Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Cannabics Pharmaceuticals Systematic Risk
Cannabics Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cannabics Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Cannabics Pharmaceuticals correlated with the market. If Beta is less than 0 Cannabics Pharmaceuticals generally moves in the opposite direction as compared to the market. If Cannabics Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cannabics Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cannabics Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Cannabics Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
About Cannabics Pharmaceuticals Financials
What exactly are Cannabics Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Cannabics Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Cannabics Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cannabics Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Cannabics Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cannabics Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Cannabics Pharmaceuticals Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Cannabics Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Cannabics has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Cannabics Pharmaceuticals' financials are consistent with your investment objective using the following steps:- Review Cannabics Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Cannabics Pharmaceuticals' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Cannabics Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Cannabics Pharmaceuticals' stock is overvalued or undervalued.
Cannabics Pharmaceuticals April 19, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cannabics Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cannabics Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cannabics Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Cannabics OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cannabics Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 47.37 | |||
Information Ratio | 0.1035 | |||
Maximum Drawdown | 150.0 | |||
Value At Risk | (50.00) | |||
Potential Upside | 100.0 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cannabics Pharmaceuticals. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Cannabics Pharmaceuticals information on this page should be used as a complementary analysis to other Cannabics Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Cannabics OTC Stock analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |